AC Epoch 125 SC Fungicide AXICHEM Pty Ltd

Chemwatch: 5294-83
Version No: 4.1

Safety Data Sheet according to WHS Regulations (Hazardous Chemicals) Amendment 2020 and ADG requirements

Chemwatch Hazard Alert Code: 2

Issue Date: **20/08/2021**Print Date: **25/02/2022**L.GHS.AUS.EN

SECTION 1 Identification of the substance / mixture and of the company / undertaking

Product name AC Epoch 125 SC Fungicide Chemical Name Not Applicable Synonyms Not Available Chemical formula Not Applicable Other means of identification Not Available

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses Agricultural fungicide.

Details of the supplier of the safety data sheet

Registered company name	AXICHEM Pty Ltd			
Address	9 Palings Court Nerang QLD 4211 Australia			
Telephone	596 1736			
Fax	lot Available			
Website	www.axichem.com.au			
Email	msds@axichem.com.au			

Emergency telephone number

	Association / Organisation	CHEMWATCH EMERGENCY RESPONSE		
Emergency telephone numbers +61 1800 951 288		+61 1800 951 288		
	Other emergency telephone numbers	+61 2 9186 1132		

Once connected and if the message is not in your prefered language then please dial 01

SECTION 2 Hazards identification

Classification of the substance or mixture

Poisons Schedule	Not Applicable				
Classification [1]	Skin Corrosion/Irritation Category 2, Serious Eye Damage/Eye Irritation Category 2A, Carcinogenicity Category 2, Reproductive Toxicity Category 1A, Hazardous to the Aquatic Environment Long-Term Hazard Category 3				
Legend:	1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI				

Label elements

Hazard pictogram(s)





Signal word

Danger

Chemwatch: **5294-83** Version No: **4.1** Page 2 of 13

AC Epoch 125 SC Fungicide

Issue Date: **20/08/2021**Print Date: **25/02/2022**

Hazard statement(s)

H315	Causes skin irritation.			
H319	uses serious eye irritation.			
H351	suspected of causing cancer.			
H360Df	May damage the unborn child. Suspected of damaging fertility.			
H412	Harmful to aquatic life with long lasting effects.			

Precautionary statement(s) Prevention

P201	Obtain special instructions before use.			
P280	protective gloves, protective clothing, eye protection and face protection.			
P273	Avoid release to the environment.			
P264	Wash all exposed external body areas thoroughly after handling.			

Precautionary statement(s) Response

P308+P313	IF exposed or concerned: Get medical advice/ attention.				
P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.				
P337+P313	ye irritation persists: Get medical advice/attention.				
P302+P352	IF ON SKIN: Wash with plenty of water.				
P332+P313	If skin irritation occurs: Get medical advice/attention.				
P362+P364	Take off contaminated clothing and wash it before reuse.				

Precautionary statement(s) Storage

P405 Store locked up.

Precautionary statement(s) Disposal

P501 Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight] Name						
133855-98-8	10-15	<u>epoxiconazole</u>					
Not Available		(131 g/L)					
57-55-6	<10	210 <u>propylene glycol</u>					
68439-50-9	<3	alcohols C12-14 ethoxylated					
Not Available	>60 Ingredients determined not to be hazardous including water						
Not Available							
7732-18-5							
Legend: 1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/20 Annex VI; 4. Classification drawn from C&L * EU IOELVs available							

SECTION 4 First aid measures

Description of first aid measures

If this product comes in contact with the eyes:

Wash out immediately with fresh running water.

Eye Contact

- Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.
- ▶ Seek medical attention without delay; if pain persists or recurs seek medical attention.
- ▶ Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.

 Chemwatch: 5294-83
 Page 3 of 13
 Issue Date: 20/08/2021

 Version No: 4.1
 AC Epoch 125 SC Fungicide
 Print Date: 25/02/2022

Skin Contact	If skin contact occurs: Immediately remove all contaminated clothing, including footwear. Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation.
Inhalation	 If fumes, aerosols or combustion products are inhaled remove from contaminated area. Other measures are usually unnecessary.
Ingestion	 If swallowed do NOT induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. Observe the patient carefully. Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. Seek medical advice

Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

SECTION 5 Firefighting measures

Extinguishing media

- ► Water spray or fog.
- ► Foam.
- Dry chemical powder.
- ▶ BCF (where regulations permit).
- Carbon dioxide.

Special hazards arising from the substrate or mixture

Fire Incompatibility	None known.				
Advice for firefighters					
 Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves in the event of a fire. Prevent, by any means available, spillage from entering drains or water courses. Use fire fighting procedures suitable for surrounding area. DO NOT approach containers suspected to be hot. Cool fire exposed containers with water spray from a protected location. If safe to do so, remove containers from path of fire. Equipment should be thoroughly decontaminated after use. 					
Fire/Explosion Hazard	 The material is not readily combustible under normal conditions. However, it will break down under fire conditions and the organic component may burn. Not considered to be a significant fire risk. Heat may cause expansion or decomposition with violent rupture of containers. Decomposes on heating and may produce toxic fumes of carbon monoxide (CO). May emit acrid smoke. Decomposes on heating and produces toxic fumes of: carbon dioxide (CO2) hydrogen chloride hydrogen fluoride nitrogen oxides (NOx) other pyrolysis products typical of burning organic material. 				
HAZCHEM	Not Applicable				

SECTION 6 Accidental release measures

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up


Minor Spills

Clean up all spills immediately.

Chemwatch: **5294-83**Version No: **4.1**

AC Epoch 125 SC Fungicide

Issue Date: **20/08/2021**Print Date: **25/02/2022**



Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling

Safe handling	 Limit all unnecessary personal contact. Wear protective clothing when risk of exposure occurs. Use in a well-ventilated area. When handling DO NOT eat, drink or smoke. Always wash hands with soap and water after handling. Avoid physical damage to containers. Use good occupational work practice. Observe manufacturer's storage and handling recommendations contained within this SDS. 			
Other information	 Store in original containers. Keep containers securely sealed. Store in a cool, dry, well-ventilated area. Store away from incompatible materials and foodstuff containers. Protect containers against physical damage and check regularly for leaks. Observe manufacturer's storage and handling recommendations contained within this SDS. 			

Conditions for safe storage, including any incompatibilities

Suitable container	 Polyethylene or polypropylene container. Packing as recommended by manufacturer. Check all containers are clearly labelled and free from leaks.
Storage incompatibility None known	

SECTION 8 Exposure controls / personal protection

Control parameters

Occupational Exposure Limits (OEL)

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
Australia Exposure Standards	propylene glycol	Propane-1,2-diol: particulates only	10 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	propylene glycol	Propane-1,2-diol total: (vapour & particulates)	150 ppm / 474 mg/m3	Not Available	Not Available	Not Available

Emergency Limits

Ingredient	TEEL-1	TEEL-2	TEEL-3
propylene glycol	30 mg/m3	1,300 mg/m3	7,900 mg/m3

Ingredient	Original IDLH	Revised IDLH
epoxiconazole	Not Available	Not Available
propylene glycol	Not Available	Not Available
alcohols C12-14 ethoxylated	Not Available	Not Available

Issue Date: **20/08/2021**Print Date: **25/02/2022**

Ingredient	Original IDLH	Revised IDLH
water	Not Available	Not Available

Occupational Exposure Banding

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit	
epoxiconazole	С	> 0.1 to ≤ milligrams per cubic meter of air (mg/m³)	
alcohols C12-14 ethoxylated	E	≤ 0.1 ppm	
Notes:	Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health.		

MATERIAL DATA

Exposure controls

Apocaro controlo	
Appropriate engineering controls	Use in a well-ventilated area General exhaust is adequate under normal operating conditions.
Personal protection	
Eye and face protection	 Safety glasses with side shields Chemical goggles. Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]
Skin protection	See Hand protection below
Hands/feet protection	 Wear chemical protective gloves, e.g. PVC. Wear safety footwear or safety gumboots, e.g. Rubber Elbow length PVC gloves
Body protection	See Other protection below
Other protection	Overalls. P.V.C apron. Barrier cream. Skin cleansing cream. Eye wash unit.

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:

"Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the ${\it computer-generated}$ selection:

AC Epoch 125 SC Fungicide

Material	СРІ
PE/EVAL/PE	A

^{*} CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

Respiratory protection

Type A-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Issue Date: **20/08/2021**Print Date: **25/02/2022**

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required. Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 5 x ES	A-AUS / Class 1 P2	-	A-PAPR-AUS / Class 1 P2
up to 25 x ES	Air-line*	A-2 P2	A-PAPR-2 P2
up to 50 x ES	-	A-3 P2	-
50+ x ES	-	Air-line**	-

^{* -} Continuous-flow; ** - Continuous-flow or positive pressure demand ^ - Full-face

 $\label{eq:A(All classes)} A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)$

SECTION 9 Physical and chemical properties

Information on basic physical and chemical properties

Appearance	Off-white liquid with aromatic solvent odour;	dispersible in water.	
Physical state	Liquid	Relative density (Water = 1)	1.05
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available
pH (as supplied)	Not Available	Decomposition temperature	Not Available
Melting point / freezing point (°C)	Not Available	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	Not Applicable	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Not Applicable	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Applicable	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Applicable	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	Not Available	Gas group	Not Available
Solubility in water	Miscible	pH as a solution (Not Available%)	Not Available
Vapour density (Air = 1)	Not Available	VOC g/L	Not Available

SECTION 10 Stability and reactivity

Reactivity	See section 7
Chemical stability	Product is considered stable and hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

Issue Date: **20/08/2021**Print Date: **25/02/2022**

SECTION 11 Toxicological information

Inhaled	,	Not normally a hazard due to non-volatile nature of product Inhalation of vapour is more likely at higher than normal temperatures.			
Ingestion	Accidental ingestion of the material may be damaging to the health of the individual. Ingestion may result in nausea, abdominal irritation, pain and vomiting Aromatase inhibitors (including triazoles and azoles) produce several side effects including mood swing, depression, weight gain, hot flushes, vaginal dryness, bloating, early onset of menopause. Long-term use may result in bone weakness, increased risk of blood clots, gastrointestinal disturbance, and sweats. Aromatase inhibitors lower the level of oestrogen in post-menopausal women who have hormone-receptor-positive breast cancers. Prior to menopause oestrogen is mostly produced in the ovaries. Post-menopausal women produce oestrogen from another hormone, androgen. Aromatase inhibitors prevent the enzyme, aromatase from catalysing this reaction. Breast cancer cell growth in post-menopausal women is stimulated by oestrogen.				
Skin Contact	The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis.				
Еуе	Evidence exists, or practical experience predicts, that the material may cause eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals. Repeated or prolonged eye contact may cause inflammation characterised by temporary redness (similar to windburn) of the				
Chronic	conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur. On the basis, primarily, of animal experiments, concern has been expressed that the material may produce carcinogenic or mutagenic effects; in respect of the available information, however, there presently exists inadequate data for making a satisfactory assessment. There is sufficient evidence to provide a strong presumption that human exposure to the material may result in developmental toxicity, generally on the basis of: - clear results in appropriate animal studies where effects have been observed in the absence of marked maternal toxicity, or at around the same dose levels as other toxic effects but which are not secondary non-specific consequences of the other toxic effects. Exposure to the material may cause concerns for human fertility, generally on the basis that results in animal studies provide sufficient evidence to cause a strong suspicion of impaired fertility in the absence of toxic effects, or evidence of impaired fertility occurring at around the same dose levels as other toxic effects, but which are not a secondary non-specific consequence of other toxic effects.				
	occurring at around the same dose levels as other tox toxic effects.				
	toxic effects.	xic effects, but which are not a secondary non-specific consequence of othe			
AC Epoch 125 SC Fungicide	-				
="	toxic effects. TOXICITY	xic effects, but which are not a secondary non-specific consequence of othe			
="	TOXICITY Not Available	ic effects, but which are not a secondary non-specific consequence of othe IRRITATION Not Available			
="	toxic effects. TOXICITY Not Available TOXICITY dermal (rat) LD50: >2000 mg/kg ^[2]	IRRITATION IRRITATION IRRITATION IRRITATION			
Fungicide	TOXICITY Not Available TOXICITY	IRRITATION IRRITATION IRRITATION IRRITATION			
Fungicide	toxic effects. TOXICITY Not Available TOXICITY dermal (rat) LD50: >2000 mg/kg ^[2] Inhalation(Rat) LC50; >5.3 mg/l4h ^[2]	IRRITATION IRRITATION IRRITATION IRRITATION			
Fungicide	toxic effects. TOXICITY Not Available TOXICITY dermal (rat) LD50: >2000 mg/kg ^[2] Inhalation(Rat) LC50; >5.3 mg/l4h ^[2] Oral (Rat) LD50; >5000 mg/kg ^[2]	IRRITATION Not Available IRRITATION Not Available			
Fungicide	toxic effects. TOXICITY Not Available TOXICITY dermal (rat) LD50: >2000 mg/kg ^[2] Inhalation(Rat) LC50; >5.3 mg/l4h ^[2] Oral (Rat) LD50; >5000 mg/kg ^[2] TOXICITY	IRRITATION Not Available IRRITATION Not Available IRRITATION IRRITATION IRRITATION IRRITATION			
Fungicide	toxic effects. TOXICITY Not Available TOXICITY dermal (rat) LD50: >2000 mg/kg ^[2] Inhalation(Rat) LC50; >5.3 mg/l4h ^[2] Oral (Rat) LD50; >5000 mg/kg ^[2] TOXICITY Dermal (rabbit) LD50: 11890 mg/kg ^[2]	IRRITATION Not Available IRRITATION Not Available IRRITATION See IRRITATION Not Available IRRITATION Eye (rabbit): 100 mg - mild			
epoxiconazole	toxic effects. TOXICITY Not Available TOXICITY dermal (rat) LD50: >2000 mg/kg ^[2] Inhalation(Rat) LC50; >5.3 mg/l4h ^[2] Oral (Rat) LD50; >5000 mg/kg ^[2] TOXICITY Dermal (rabbit) LD50: 11890 mg/kg ^[2] Inhalation(Rat) LC50; >44.9 mg/L4h ^[2]	IRRITATION Not Available IRRITATION Not Available IRRITATION Not Available IRRITATION Eye (rabbit): 100 mg - mild Eye (rabbit): 500 mg/24h - mild			
epoxiconazole	toxic effects. TOXICITY Not Available TOXICITY dermal (rat) LD50: >2000 mg/kg ^[2] Inhalation(Rat) LC50; >5.3 mg/l4h ^[2] Oral (Rat) LD50; >5000 mg/kg ^[2] TOXICITY Dermal (rabbit) LD50: 11890 mg/kg ^[2] Inhalation(Rat) LC50; >44.9 mg/L4h ^[2]	IRRITATION Not Available IRRITATION Not Available IRRITATION Not Available IRRITATION Eye (rabbit): 100 mg - mild Eye (rabbit): 500 mg/24h - mild Eye: no adverse effect observed (not irritating)[1]			
epoxiconazole	toxic effects. TOXICITY Not Available TOXICITY dermal (rat) LD50: >2000 mg/kg ^[2] Inhalation(Rat) LC50; >5.3 mg/l4h ^[2] Oral (Rat) LD50; >5000 mg/kg ^[2] TOXICITY Dermal (rabbit) LD50: 11890 mg/kg ^[2] Inhalation(Rat) LC50; >44.9 mg/L4h ^[2]	IRRITATION Not Available IRRITATION Not Available IRRITATION Not Available IRRITATION Eye (rabbit): 100 mg - mild Eye (rabbit): 500 mg/24h - mild Eye: no adverse effect observed (not irritating) ^[1] Skin(human):104 mg/3d Intermit Mod			
epoxiconazole	toxic effects. TOXICITY Not Available TOXICITY dermal (rat) LD50: >2000 mg/kg ^[2] Inhalation(Rat) LC50; >5.3 mg/l4h ^[2] Oral (Rat) LD50; >5000 mg/kg ^[2] TOXICITY Dermal (rabbit) LD50: 11890 mg/kg ^[2] Inhalation(Rat) LC50; >44.9 mg/L4h ^[2]	IRRITATION Not Available IRRITATION Not Available IRRITATION Not Available IRRITATION Sepe (rabbit): 100 mg - mild Eye (rabbit): 500 mg/24h - mild Eye: no adverse effect observed (not irritating)[1] Skin(human):104 mg/3d Intermit Mod Skin(human):500 mg/7days mild			
epoxiconazole	toxic effects. TOXICITY Not Available TOXICITY dermal (rat) LD50: >2000 mg/kg ^[2] Inhalation(Rat) LC50; >5.3 mg/l4h ^[2] Oral (Rat) LD50; >5000 mg/kg ^[2] TOXICITY Dermal (rabbit) LD50: 11890 mg/kg ^[2] Inhalation(Rat) LC50; >44.9 mg/L4h ^[2] Oral (Rat) LD50; 20000 mg/kg ^[2]	IRRITATION Not Available IRRITATION Not Available IRRITATION Not Available IRRITATION Not Available IRRITATION Eye (rabbit): 100 mg - mild Eye (rabbit): 500 mg/24h - mild Eye: no adverse effect observed (not irritating) ^[1] Skin(human):104 mg/3d Intermit Mod Skin(human):500 mg/7days mild Skin: no adverse effect observed (not irritating) ^[1]			
epoxiconazole propylene glycol alcohols C12-14	toxic effects. TOXICITY Not Available TOXICITY dermal (rat) LD50: >2000 mg/kg ^[2] Inhalation(Rat) LC50; >5.3 mg/l4h ^[2] Oral (Rat) LD50; >5000 mg/kg ^[2] TOXICITY Dermal (rabbit) LD50: 11890 mg/kg ^[2] Inhalation(Rat) LC50; >44.9 mg/L4h ^[2] Oral (Rat) LD50; 20000 mg/kg ^[2]	IRRITATION Not Available IRRITATION Not Available IRRITATION Not Available IRRITATION Not Available IRRITATION Eye (rabbit): 100 mg - mild Eye (rabbit): 500 mg/24h - mild Eye: no adverse effect observed (not irritating) ^[1] Skin(human):104 mg/3d Intermit Mod Skin(human):500 mg/7days mild Skin: no adverse effect observed (not irritating) ^[1] IRRITATION			
epoxiconazole propylene glycol	toxic effects. TOXICITY Not Available TOXICITY dermal (rat) LD50: >2000 mg/kg ^[2] Inhalation(Rat) LC50; >5.3 mg/l4h ^[2] Oral (Rat) LD50: >5000 mg/kg ^[2] TOXICITY Dermal (rabbit) LD50: 11890 mg/kg ^[2] Inhalation(Rat) LC50; >44.9 mg/L4h ^[2] Oral (Rat) LD50; 20000 mg/kg ^[2] TOXICITY dermal (rat) LD50: >=2000 mg/kg ^[1]	IRRITATION Not Available IRRITATION Not Available IRRITATION Not Available IRRITATION Eye (rabbit): 100 mg - mild Eye (rabbit): 500 mg/24h - mild Eye: no adverse effect observed (not irritating) ^[1] Skin(human):104 mg/3d Intermit Mod Skin(human):500 mg/7days mild Skin: no adverse effect observed (not irritating) ^[1] IRRITATION Eye (rabbit): irritant *			
epoxiconazole propylene glycol alcohols C12-14	toxic effects. TOXICITY Not Available TOXICITY dermal (rat) LD50: >2000 mg/kg ^[2] Inhalation(Rat) LC50; >5.3 mg/l4h ^[2] Oral (Rat) LD50; >5000 mg/kg ^[2] TOXICITY Dermal (rabbit) LD50: 11890 mg/kg ^[2] Inhalation(Rat) LC50; >44.9 mg/L4h ^[2] Oral (Rat) LD50; 20000 mg/kg ^[2] TOXICITY dermal (rat) LD50: >=2000 mg/kg ^[1] Inhalation(Rat) LC50; >1.6 mg/l4h ^[1]	IRRITATION Not Available IRRITATION Not Available IRRITATION Not Available IRRITATION Not Available IRRITATION Eye (rabbit): 100 mg - mild Eye (rabbit): 500 mg/24h - mild Eye: no adverse effect observed (not irritating) ^[1] Skin(human):104 mg/3d Intermit Mod Skin(human):500 mg/7days mild Skin: no adverse effect observed (not irritating) ^[1] IRRITATION Eye (rabbit): irritant * Eye: no adverse effect observed (not irritating) ^[1]			
epoxiconazole propylene glycol alcohols C12-14	toxic effects. TOXICITY Not Available TOXICITY dermal (rat) LD50: >2000 mg/kg ^[2] Inhalation(Rat) LC50; >5.3 mg/l4h ^[2] Oral (Rat) LD50; >5000 mg/kg ^[2] TOXICITY Dermal (rabbit) LD50: 11890 mg/kg ^[2] Inhalation(Rat) LC50; >44.9 mg/L4h ^[2] Oral (Rat) LD50; 20000 mg/kg ^[2] TOXICITY dermal (rat) LD50: >=2000 mg/kg ^[1] Inhalation(Rat) LC50; >1.6 mg/l4h ^[1]	IRRITATION Not Available IRRITATION Not Available IRRITATION Not Available IRRITATION Eye (rabbit): 100 mg - mild Eye (rabbit): 500 mg/24h - mild Eye: no adverse effect observed (not irritating) ^[1] Skin(human):104 mg/3d Intermit Mod Skin(human):500 mg/7days mild Skin: no adverse effect observed (not irritating) ^[1] IRRITATION Eye (rabbit): irritant * Eye: no adverse effect observed (not irritating) ^[1] Skin (rabbit): irritant *			

Chemwatch: **5294-83**Version No: **4.1**

Page 8 of 13 AC Epoch 125 SC Fungicide

Issue Date: **20/08/2021**Print Date: **25/02/2022**

Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances

The acute oral toxicity of propylene glycol is very low, and large quantities are required to cause perceptible health damage in humans. Serious toxicity generally occurs only at plasma concentrations over 1 g/L, which requires extremely high intake over a relatively short period of time. It would be nearly impossible to reach toxic levels by consuming foods or supplements, which contain at most 1 g/kg of PG. Cases of propylene glycol poisoning are usually related to either inappropriate intravenous administration or accidental ingestion of large quantities by children. The potential for long-term oral toxicity is also low. Because of its low chronic oral toxicity, propylene glycol was classified by the U. S. Food and Drug Administration as "generally recognized as safe" (GRAS) for use as a direct food additive.

Prolonged contact with propylene glycol is essentially non-irritating to the skin. Undiluted propylene glycol is minimally irritating to the eye, and can produce slight transient conjunctivitis (the eye recovers after the exposure is removed). Exposure to mists may cause eye irritation, as well as upper respiratory tract irritation. Inhalation of the propylene glycol vapours appears to present no significant hazard in ordinary applications. However, limited human experience indicates that inhalation of propylene glycol mists could be irritating to some individuals It is therefore recommended that propylene glycol not be used in applications where inhalation exposure or human eye contact with the spray mists of these materials is likely, such as fogs for theatrical productions or antifreeze solutions for emergency eye wash stations.

Propylene glycol is metabolised in the human body into pyruvic acid (a normal part of the glucose-metabolism process, readily converted to energy), acetic acid (handled by ethanol-metabolism), lactic acid (a normal acid generally abundant during digestion), and propional dehyde (a potentially hazardous substance).

Propylene glycol shows no evidence of being a carcinogen or of being genotoxic.

Research has suggested that individuals who cannot tolerate propylene glycol probably experience a special form of irritation, but that they only rarely develop allergic contact dermatitis. Other investigators believe that the incidence of allergic contact dermatitis to propylene glycol may be greater than 2% in patients with eczema.

One study strongly suggests a connection between airborne concentrations of propylene glycol in houses and development of asthma and allergic reactions, such as rhinitis or hives in children

Another study suggested that the concentrations of PGEs (counted as the sum of propylene glycol and glycol ethers) in indoor air, particularly bedroom air, is linked to increased risk of developing numerous respiratory and immune disorders in children, including asthma, hay fever, eczema, and allergies, with increased risk ranging from 50% to 180%. This concentration has been linked to use of water-based paints and water-based system cleansers.

Patients with vulvodynia and interstitial cystitis may be especially sensitive to propylene glycol. Women suffering with yeast infections may also notice that some over the counter creams can cause intense burning. Post menopausal women who require the use of an eostrogen cream may notice that brand name creams made with propylene glycol often create extreme, uncomfortable burning along the vulva and perianal area. Additionally, some electronic cigarette users who inhale propylene glycol vapor may experience dryness of the throat or shortness of breath. As an alternative, some suppliers will put Vegetable Glycerin in the "e-liquid" for those who are allergic (or have bad reactions) to propylene glycol.

Adverse responses to intravenous administration of drugs which use PG as an excipient have been seen in a number of people, particularly with large dosages thereof. Responses may include "hypotension, bradycardia... QRS and T abnormalities on the ECG, arrhythmia, cardiac arrest, serum hyperosmolality, lactic acidosis, and haemolysis". A high percentage (12% to 42%) of directly-injected propylene glycol is eliminated/secreted in urine unaltered depending on dosage, with the remainder appearing in its glucuronide-form. The speed of renal filtration decreases as dosage increases, which may be due to propylene glycol's mild anesthetic / CNS-depressant -properties as an alcohol. In one case, intravenous administration of propylene glycol-suspended nitroglycerin to an elderly man may have induced coma and acidosis.

Propylene glycol is an approved food additive for dog food under the category of animal feed and is generally recognized as safe for dogs with an LD50 of 9 mL/kg. The LD50 is higher for most laboratory animals (20 mL/kg)

Similarly, propylene glycol is an approved food additive for human food as well. The exception is that it is prohibited for use in

food for cats due to links to Heinz body anemia.

* BASF Canada ** [Henkel CCINFO 1450373]

Human beings have regular contact with alcohol ethoxylates through a variety of industrial and consumer products such as soaps, detergents, and other cleaning products. Exposure to these chemicals can occur through ingestion, inhalation, or contact with the skin or eyes. Studies of acute toxicity show that volumes well above a reasonable intake level would have to occur to produce any toxic response. Moreover, no fatal case of poisoning with alcohol ethoxylates has ever been reported. Multiple studies investigating the acute toxicity of alcohol ethoxylates have shown that the use of these compounds is of low concern in terms of oral and dermal toxicity.

Clinical animal studies indicate these chemicals may produce gastrointestinal irritation such as ulcerations of the stomach, pilo-erection, diarrhea, and lethargy. Similarly, slight to severe irritation of the skin or eye was generated when undiluted alcohol ethoxylates were applied to the skin and eyes of rabbits and rats. The chemical shows no indication of being a genotoxin, carcinogen, or mutagen (HERA 2007). No information was available on levels at which these effects might occur, though toxicity is thought to be substantially lower than that of nonylphenol ethoxylates.

is thought to be substantially lower than that of nonylphenol ethoxylates.

Polyethers, for example, ethoxylated surfactants and polyethylene glycols, are highly susceptible towards air oxidation as the ether oxygens will stabilize intermediary radicals involved. Investigations of a chemically well-defined alcohol (pentaethylene glycol mono-n-dodecyl ether) ethoxylate, showed that polyethers form complex mixtures of oxidation products when exposed to

Sensitization studies in guinea pigs revealed that the pure nonoxidized surfactant itself is nonsensitizing but that many of the investigated oxidation products are sensitizers. Two hydroperoxides were identified in the oxidation mixture, but only one (16-hydroperoxy-3,6,9,12,15-pentaoxaheptacosan-1-ol) was stable enough to be isolated. It was found to be a strong sensitizer in LLNA (local lymph node assay for detection of sensitization capacity). The formation of other hydroperoxides was indicated by the detection of their corresponding aldehydes in the oxidation mixture.

On the basis of the lower irritancy, nonionic surfactants are often preferred to ionic surfactants in topical products. However, their susceptibility towards autoxidation also increases the irritation. Because of their irritating effect, it is difficult diagnose ACD to these compounds by patch testing.

Alcohol ethoxylates are according to CESIO (2000) classified as Irritant or Harmful depending on the number of EO-units:

ALCOHOLS C12-14 ETHOXYLATED

air.

PROPYLENE GLYCOL

Continued...

Issue Date: **20/08/2021**Print Date: **25/02/2022**

EO < 5 gives Irritant (Xi) with R38 (Irritating to skin) and R41 (Risk of serious damage to eyes)

EO > 5-15 gives Harmful (Xn) with R22 (Harmful if swallowed) - R38/41

EO > 15-20 gives Harmful (Xn) with R22-41

>20 EO is not classified (CESIO 2000)

Oxo-AE, C13 EO10 and C13 EO15, are Irritating (Xi) with R36/38 (Irritating to eyes and skin) .

AE are not included in Annex 1 of the list of dangerous substances of the Council Directive 67/548/EEC

In general, alcohol ethoxylates (AE) are readily absorbed through the skin of guinea pigs and rats and through the gastrointestinal mucosa of rats. AE are quickly eliminated from the body through the urine, faeces, and expired air (CO2). Orally dosed AE was absorbed rapidly and extensively in rats, and more than 75% of the dose was absorbed. When applied to the skin of humans, the doses were absorbed slowly and incompletely (50% absorbed in 72 hours). Half of the absorbed surfactant was excreted promptly in the urine and smaller amounts of AE appeared in the faeces and expired air (CO2)). The metabolism of C12 AE yields PEG, carboxylic acids, and CO2 as metabolites. The LD50 values after oral administration to rats range from about 1-15 g/kg body weight indicating a low to moderate acute toxicity.

The ability of nonionic surfactants to cause a swelling of the stratum corneum of guinea pig skin has been studied. The swelling mechanism of the skin involves a combination of ionic binding of the hydrophilic group as well as hydrophobic interactions of the alkyl chain with the substrate. One of the mechanisms of skin irritation caused by surfactants is considered to be denaturation of the proteins of skin. It has also been established that there is a connection between the potential of surfactants to denature protein in vitro and their effect on the skin. Nonionic surfactants do not carry any net charge and, therefore, they can only form hydrophobic bonds with proteins. For this reason, proteins are not deactivated by nonionic surfactants, and proteins with poor solubility are not solubilized by nonionic surfactants. A substantial amount of toxicological data and information in vivo and in vitro demonstrates that there is no evidence for alcohol ethoxylates (AEs) being genotoxic, mutagenic or carcinogenic. No adverse reproductive or developmental effects were observed. The majority of available toxicity studies revealed NOAELs in excess of 100 mg/kg bw/d but the lowest NOAEL for an individual AE was established to be 50 mg/kg bw/day. This value was subsequently considered as a conservative, representative value in the risk assessment of AE. The effects were restricted to changes in organ weights with no histopathological organ changes with the exception of liver hypertrophy (indicative of an adaptive response to metabolism rather than a toxic effect). It is noteworthy that there was practically no difference in the NOAEL in oral studies of 90-day or 2 years of duration in rats. A comparison of the aggregate consumer exposure and the systemic NOAEL (taking into account an oral absorption value of 75%) results in a Margin of Exposure of 5,800. Taking into account the conservatism in the exposure assessment and the assigned systemic NOAEL, this margin of exposure is considered more than adequate to account for the inherent uncertainty and variability of the hazard database and inter and intra-species extrapolations.

AEs are not contact sensitisers. Neat AE are irritating to eyes and skin. The irritation potential of aqueous solutions of AEs depends on concentrations. Local dermal effects due to direct or indirect skin contact in certain use scenarios where the products are diluted are not of concern as AEs are not expected to be irritating to the skin at in-use concentrations. Potential irritation of the respiratory tract is not a concern given the very low levels of airborne AE generated as a consequence of spray cleaner aerosols or laundry powder detergent dust.

In summary, the human health risk assessment has demonstrated that the use of AE in household laundry and cleaning detergents is safe and does not cause concern with regard to consumer use.

For high boiling ethylene glycol ethers (typically triethylene- and tetraethylene glycol ethers):

Skin absorption: Available skin absorption data for triethylene glycol ether (TGBE), triethylene glycol methyl ether (TGME), and triethylene glycol ethylene ether (TGEE) suggest that the rate of absorption in skin of these three glycol ethers is 22 to 34 micrograms/cm2/hr, with the methyl ether having the highest permeation constant and the butyl ether having the lowest. The rates of absorption of TGBE, TGEE and TGME are at least 100-fold less than EGME, EGEE, and EGBE, their ethylene glycol monoalkyl ether counterparts, which have absorption rates that range from 214 to 2890 micrograms/ cm2/hr. Therefore, an increase in either the chain length of the alkyl substituent or the number of ethylene glycol moieties appears to lead to a decreased rate of percutaneous absorption. However, since the ratio of the change in values of the ethylene glycol to the diethylene glycol series is larger than that

of the diethylene glycol to triethylene glycol series, the effect of the length of the chain and number of ethylene glycol moieties on absorption diminishes with an increased number of ethylene glycol moieties. Therefore, although tetraethylene glycol methyl; ether (TetraME) and tetraethylene glycol butyl ether (TetraBE) are expected to be less permeable to skin than TGME and TGBE, the differences in permeation between these molecules may only be slight.

Metabolism: The main metabolic pathway for metabolism of ethylene glycol monoalkyl ethers (EGME, EGEE, and EGBE) is oxidation via alcohol and aldehyde dehydrogenases (ALD/ADH) that leads to the formation of an alkoxy acids. Alkoxy acids are the only toxicologically significant metabolites of glycol ethers that have been detected *in vivo*. The principal metabolite of TGME is believed to be 2-[2-(2-methoxyethoxy)ethoxy] acetic acid. Although ethylene glycol, a known kidney toxicant, has been identified as an impurity or a minor metabolite of glycol ethers in animal studies it does not appear to contribute to the toxicity of glycol ethers.

The metabolites of category members are not likely to be metabolized to any large extent to toxic molecules such as ethylene glycol or the mono alkoxy acids because metabolic breakdown of the ether linkages also has to occur

Acute toxicity: Category members generally display low acute toxicity by the oral, inhalation and dermal routes of exposure. Signs of toxicity in animals receiving lethal oral doses of TGBE included loss of righting reflex and flaccid muscle tone, coma, and heavy breathing. Animals administered lethal oral doses of TGEE exhibited lethargy, ataxia, blood in the urogenital area and piloerection before death.

Irritation: The data indicate that the glycol ethers may cause mild to moderate skin irritation. TGEE and TGBE are highly irritating to the eyes. Other category members show low eye irritation.

Repeat dose toxicity: Results of these studies suggest that repeated exposure to moderate to high doses of the glycol ethers in this category is required to produce systemic toxicity

In a 21-day dermal study, TGME, TGEE, and TGBE were administered to rabbits at 1,000 mg/kg/day. Erythema and oedema were observed. In addition, testicular degeneration (scored as trace in severity) was observed in one rabbit given TGEE and one

Page 10 of 13 AC Epoch 125 SC Fungicide

Issue Date: **20/08/2021**Print Date: **25/02/2022**

rabbit given TGME. Testicular effects included spermatid giant cells, focal tubular hypospermatogenesis, and increased cytoplasmic vacuolisation . Due to a high incidence of similar spontaneous changes

in normal New Zealand White rabbits , the testicular effects were considered not to be related to treatment . Thus, the NOAELs for TGME, TGEE and TGBE were established at 1000 mg/kg/day. Findings from this report were considered unremarkable.

A 2-week dermal study was conducted in rats administered TGME at doses of 1,000, 2,500, and 4,000 mg/kg/day. In this study, significantly-increased red blood cells at 4,000 mg/kg/day and significantly-increased urea concentrations in the urine at 2,500 mg/kg/day were observed. A few of the rats given 2,500 or 4,000 mg/kg/day had watery caecal contents and/or haemolysed blood in the stomach These gross pathologic observations were not associated with any histologic abnormalities in these tissues or alterations in haematologic and clinical chemistry parameters. A few males and females treated with either 1,000 or 2,500 mg/kg/day had a few small scabs or crusts at the test site. These alterations were slight in degree and did not adversely affect the rats

In a 13-week drinking water study, TGME was administered to rats at doses of 400, 1,200, and 4,000 mg/kg/day. Statistically-significant changes in relative liver weight were observed at 1,200 mg/kg/day and higher. Histopathological effects included hepatocellular cytoplasmic vacuolisation (minimal to mild in most animals) and hypertrophy (minimal to mild) in males at all doses and hepatocellular hypertrophy (minimal to mild) in high dose females. These effects were statistically significant at 4,000 mg/kg/day. Cholangiofibrosis was observed in 7/15 high-dose males; this effect was observed in a small number of bile ducts and was of mild severity. Significant, small decreases in total test session motor activity were observed in the high-dose animals, but no other neurological effects were observed. The changes in motor activity were secondary to systemic toxicity

Mutagenicity: Mutagenicity studies have been conducted for several category members. All in vitro and in vivo studies were negative at concentrations up to 5,000 micrograms/plate and 5,000 mg/kg, respectively, indicating that the category members are not genotoxic at the concentrations used in these studies. The uniformly negative outcomes of various mutagenicity studies performed on category members lessen the concern for carcinogenicity.

Reproductive toxicity: Although mating studies with either the category members or surrogates have not been performed, several of the repeated dose toxicity tests with the surrogates have included examination of reproductive organs. A lower molecular weight glycol ether, ethylene glycol methyl ether (EGME), has been shown to be a testicular toxicant. In addition, results of repeated dose toxicity tests with TGME clearly show testicular toxicity at an oral dose of 4,000 mg/kg/day four times greater that the limit dose of 1,000 mg/kg/day recommended for repeat dose studies. It should be noted that TGME is 350 times less potent for testicular effects than EGME. TGBE is not associated with testicular toxicity, TetraME is not likely to be metabolised by any large extent to 2-MAA (the toxic metabolite of EGME), and a mixture containing predominantly methylated glycol ethers in the C5-C11 range does not produce testicular toxicity (even when administered intravenously at 1,000 mg/kg/day).

Developmental toxicity: The bulk of the evidence shows that effects on the foetus are not noted in treatments with . 1,000 mg/kg/day during gestation. At 1,250 to 1,650 mg/kg/day TGME (in the rat) and 1,500 mg/kg/day (in the rabbit), the developmental effects observed included skeletal variants and decreased body weight gain.

The material may produce severe irritation to the eye causing pronounced inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis.

EPOXICONAZOLE & WATER

No significant acute toxicological data identified in literature search.

PROPYLENE GLYCOL & ALCOHOLS C12-14 ETHOXYLATED

The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling the epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis.

Acute Toxicity	×	Carcinogenicity	✓
Skin Irritation/Corrosion	✓	Reproductivity	✓
Serious Eye Damage/Irritation	✓	STOT - Single Exposure	×
Respiratory or Skin sensitisation	×	STOT - Repeated Exposure	×
Mutagenicity	×	Aspiration Hazard	×

Legend:

X − Data either not available or does not fill the criteria for classification

→ − Data available to make classification

SECTION 12 Ecological information

Toxicity

40 Frank 405 00	Endpoint	Test Duration (hr)	Species	Value	Source
AC Epoch 125 SC Fungicide	Not Available	Not Available	Not Available	Not Available	Not Available
	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	72h	Fish	0.2mg/l	4
epoxiconazole	LC50	96h	Fish	<4.6mg/l	2
	EC50	72h	Algae or other aquatic plants	2.31mg/l	2

Issue Date: 20/08/2021 Print Date: 25/02/2022

	EC50	48h	Crustacea	5.276mg/L	4
	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	336h	Algae or other aquatic plants	<5300mg/l	1
	LC50	96h	Fish	>10000mg/l	2
propylene glycol	EC50	72h	Algae or other aquatic plants	19300mg/l	2
	EC50	48h	Crustacea	>114.4mg/L	4
	EC50	96h	Algae or other aquatic plants	19000mg/l	2
	Endpoint	Test Duration (hr)	Species	Value	Source
	EC0(ECx)	72h	Algae or other aquatic plants	0.035mg/l	2
alcohols C12-14 ethoxylated	LC50	96h	Fish	1.1mg/l	2
	EC50	72h	Algae or other aquatic plants	0.13mg/l	2
	EC50	48h	Crustacea	0.53mg/l	2
	Endpoint	Test Duration (hr)	Species	Value	Source
water	Not Available	Not Available	Not Available	Not Available	Not Available
Legend:	Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 8. Vendor Data				

Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

DO NOT discharge into sewer or waterways.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
propylene glycol	LOW	LOW
water	LOW	LOW

Bioaccumulative potential

Ingredient	Bioaccumulation	
propylene glycol	LOW (BCF = 1)	

Mobility in soil

Ingredient	Mobility
propylene glycol	HIGH (KOC = 1)

SECTION 13 Disposal considerations

Waste treatment methods

Product / Packaging disposal

- ▶ Recycle wherever possible or consult manufacturer for recycling options.
- ► Consult State Land Waste Management Authority for disposal.
- Bury residue in an authorised landfill.
- ▶ Recycle containers if possible, or dispose of in an authorised landfill.

SECTION 14 Transport information

Labels Required

<u> </u>	
Marine Pollutant	NO
HAZCHEM	Not Applicable

Land transport (ADG): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Issue Date: **20/08/2021**Print Date: **25/02/2022**

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
epoxiconazole	Not Available
propylene glycol	Not Available
alcohols C12-14 ethoxylated	Not Available
water	Not Available

Transport in bulk in accordance with the ICG Code

Product name	Ship Type
epoxiconazole	Not Available
propylene glycol	Not Available
alcohols C12-14 ethoxylated	Not Available
water	Not Available

SECTION 15 Regulatory information

Safety, health and environmental regulations / legislation specific for the substance or mixture

epoxiconazole is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5

Chemical Footprint Project - Chemicals of High Concern List International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

propylene glycol is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

alcohols C12-14 ethoxylated is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals

Australian Inventory of Industrial Chemicals (AIIC)

water is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

National Inventory Status

National Inventory	Status		
Australia - AIIC / Australia Non-Industrial Use	No (epoxiconazole)		
Canada - DSL	No (epoxiconazole)		
Canada - NDSL	No (epoxiconazole; propylene glycol; alcohols C12-14 ethoxylated; water)		
China - IECSC	Yes		
Europe - EINEC / ELINCS / NLP	Yes		
Japan - ENCS	No (epoxiconazole)		
Korea - KECI	No (epoxiconazole)		
New Zealand - NZIoC	Yes		
Philippines - PICCS	Yes		
USA - TSCA	No (epoxiconazole)		
Taiwan - TCSI	Yes		
Mexico - INSQ	No (alcohols C12-14 ethoxylated)		
Vietnam - NCI	Yes		
Russia - FBEPH	No (epoxiconazole)		

Version No: 4.1

AC Epoch 125 SC Fungicide

Issue Date: 20/08/2021 Print Date: 25/02/2022

National Inventory	Status		
Legend:	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.		

SECTION 16 Other information

Revision Date	20/08/2021
Initial Date	27/02/2018

SDS Version Summary

Version	Date of Update	Sections Updated
3.1	01/11/2019	One-off system update. NOTE: This may or may not change the GHS classification
4.1	20/08/2021	Classification change due to full database hazard calculation/update.

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

PC-TWA: Permissible Concentration-Time Weighted Average

PC-STEL: Permissible Concentration-Short Term Exposure Limit

IARC: International Agency for Research on Cancer

ACGIH: American Conference of Governmental Industrial Hygienists

STEL: Short Term Exposure Limit

TEEL: Temporary Emergency Exposure Limit $_{\circ}$

IDLH: Immediately Dangerous to Life or Health Concentrations

ES: Exposure Standard
OSF: Odour Safety Factor

NOAEL :No Observed Adverse Effect Level LOAEL: Lowest Observed Adverse Effect Level

TLV: Threshold Limit Value LOD: Limit Of Detection OTV: Odour Threshold Value

BCF: BioConcentration Factors BEI: Biological Exposure Index

AIIC: Australian Inventory of Industrial Chemicals

DSL: Domestic Substances List NDSL: Non-Domestic Substances List

IECSC: Inventory of Existing Chemical Substance in China

EINECS: European INventory of Existing Commercial chemical Substances

ELINCS: European List of Notified Chemical Substances

NLP: No-Longer Polymers

ENCS: Existing and New Chemical Substances Inventory

KECI: Korea Existing Chemicals Inventory NZIoC: New Zealand Inventory of Chemicals

PICCS: Philippine Inventory of Chemicals and Chemical Substances

TSCA: Toxic Substances Control Act

TCSI: Taiwan Chemical Substance Inventory

INSQ: Inventario Nacional de Sustancias Químicas

NCI: National Chemical Inventory

FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.